Lista de obras - Crystal Watson - Dominio Público Uruguay

A National Plan to Enable Comprehensive COVID-19 Case Finding and Contact Tracing in the US ⬇️

Plan proposal to establish contact tracing forces to address the COVID-19 pandemic in the United States

A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy

artículo científico publicado en 2013

A cross-sectional analysis of cardiovascular disease in the hemophilia population

artículo científico publicado en 2018

Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States ⬇️

artículo científico publicado el 8 de diciembre de 2011

Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey

artículo científico publicado en 2017

Clade X: A Pandemic Exercise

artículo científico publicado en 2019

Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis

artículo científico

Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden

artículo científico publicado en 2014

Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population

artículo científico publicado en 2013

Dosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care population

artículo científico publicado en 2013

Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan

artículo científico publicado en 2012

Etanercept treatment patterns in managed-care patients with psoriasis or psoriatic arthritis

scientific article published on January 2010

Factors Associated With the Initiation of Disease-Modifying Antirheumatic Drugs in Newly Diagnosed Rheumatoid Arthritis: A Retrospective Claims Database Study ⬇️

artículo científico publicado el 28 de enero de 2012

Federal Funding for Health Security in FY2018.

artículo científico publicado en 2017

Federal Funding for Health Security in FY2019

article

Frequency of Risk-Related News Media Messages in 2016 Coverage of Zika Virus

artículo científico publicado en 2018

Global Catastrophic Biological Risks: Toward a Working Definition

artículo científico publicado en 2017

Health care resource utilization before and after natalizumab initiation among patients with multiple sclerosis in Germany

artículo científico publicado en 2017

Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US.

artículo científico publicado en 2013

Impact of etanercept on work and activity impairment in employed moderate to severe rheumatoid arthritis patients in the United States

artículo científico publicado en 2013

Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis

artículo científico publicado en 2017

Multiple sclerosis patients who are stable on interferon therapy show better outcomes when staying on same therapy than patients who switch to another interferon

artículo científico publicado en 2018

Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients

artículo científico publicado en 2015

Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan population

artículo científico publicado en 2012

Risk-Based Decision Making During Public Health Emergencies Involving Environmental Contamination

Short- and longer-term health-care resource utilization and costs associated with acute ischemic stroke

artículo científico publicado en 2016

The Joint External Evaluation of Taiwan: The External Evaluators' Perspective

artículo científico publicado en 2017

Treatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sample

artículo científico publicado en 2014

Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States

artículo científico publicado en 2013

Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings

artículo científico

Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting

artículo científico publicado en 2013

Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks

artículo científico publicado en 2018

Vector control in Zika-affected communities: Local views on community engagement and public health ethics during outbreaks

artículo científico publicado en 2020

Lista de obras de Crystal Watson

A National Plan to Enable Comprehensive COVID-19 Case Finding and Contact Tracing in the US ⬇️

A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy

A cross-sectional analysis of cardiovascular disease in the hemophilia population

Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States ⬇️

Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey

Clade X: A Pandemic Exercise

Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis

Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden

Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population

Dosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care population

Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan

Etanercept treatment patterns in managed-care patients with psoriasis or psoriatic arthritis

Factors Associated With the Initiation of Disease-Modifying Antirheumatic Drugs in Newly Diagnosed Rheumatoid Arthritis: A Retrospective Claims Database Study ⬇️

Federal Funding for Health Security in FY2018.

Federal Funding for Health Security in FY2019

Frequency of Risk-Related News Media Messages in 2016 Coverage of Zika Virus

Global Catastrophic Biological Risks: Toward a Working Definition

Health care resource utilization before and after natalizumab initiation among patients with multiple sclerosis in Germany

Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US.

Impact of etanercept on work and activity impairment in employed moderate to severe rheumatoid arthritis patients in the United States

Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis

Multiple sclerosis patients who are stable on interferon therapy show better outcomes when staying on same therapy than patients who switch to another interferon

Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients

Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan population

Risk-Based Decision Making During Public Health Emergencies Involving Environmental Contamination

Short- and longer-term health-care resource utilization and costs associated with acute ischemic stroke

The Joint External Evaluation of Taiwan: The External Evaluators' Perspective

Treatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sample

Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States

Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings

Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting

Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks

Vector control in Zika-affected communities: Local views on community engagement and public health ethics during outbreaks